Theravance Biopharma, Inc. filed a Form 8-K on September 10, 2026, disclosing three shareholder lawsuits and thirteen demand letters related to its planned merger with Zymeworks Inc., and voluntarily supplementing its previously filed proxy statement with additional background disclosures.

Key Highlights

  • Merger agreement: Theravance Biopharma entered into an Agreement and Plan of Merger with Zymeworks Inc. on June 28, 2026, with a wholly owned Zymeworks subsidiary merging into the company.
  • Shareholder meeting: An extraordinary general meeting is scheduled for September 18, 2026, at 1:30 p.m. Pacific Time, at 901 Gateway Boulevard, South San Francisco, California 94080, to vote on the merger.
  • Three complaints filed: As of September 10, 2026, three individual actions have been filed by purported shareholders against the company, its board members, and in one case, Zymeworks as Parent.
  • Thirteen demand letters received: The company has also received thirteen demand letters from law firms representing purported shareholders, generally alleging disclosure deficiencies in the proxy statement.
  • Company denies allegations: According to the filing, the company and other named defendants "deny all allegations in the Matters and believe that the Matters are without merit."
  • Voluntary supplement: The company stated it is supplementing the proxy statement "solely to minimize the burden and expense of potential litigation" and to provide additional information to shareholders, not as an admission of legal necessity or materiality.
  • Outreach scope: According to the supplemental disclosures, Lazard contacted eighteen potential counterparties between February and March 2025, with the company entering confidentiality agreements with twelve of them.

Theravance Biopharma Supplements Proxy Disclosures as Merger Litigation Emerges

Theravance Biopharma, Inc. (NASDAQ:TBPH) disclosed in its September 10, 2026 Form 8-K that three complaints have been filed in connection with its pending merger with Zymeworks Inc. The complaints, captioned Richardson v. Theravance Biopharma, Inc. et al. (N.Y. Sup. Ct., filed Aug. 25, 2026), Thompson v. Theravance Biopharma, Inc. et al., Index No. 654951/2026 (N.Y. Sup. Ct., filed Aug. 26, 2026), and Maglione v. Susannah Gray et al., Case No. 26-CVI-06915 (Cal. Super. Ct. San Mateo Cnty., filed Sep. 2, 2026), seek to enjoin the merger unless additional information is disclosed, and seek rescission and/or damages if the merger is consummated.

The company reported that, in addition to the three complaints, it had received thirteen demand letters from law firms as of the filing date, all generally alleging disclosure deficiencies in the definitive proxy statement filed with the SEC on August 21, 2026. The filing stated that the company and its co-defendants deny all allegations and consider the matters without merit, adding that "no supplemental disclosure to the Proxy Statement was or is required under any applicable law, rule or regulation."

Nonetheless, the company chose to voluntarily supplement the proxy statement. The supplemental disclosures amend and restate several paragraphs in the "Background of the Merger" section, including details about confidentiality agreements signed with twelve of eighteen potential counterparties contacted by Lazard, standstill provisions applicable to those parties, and the receipt of bids from three parties including GlaxoSmithKline Intellectual Property Development Limited. The filing explicitly states that the supplemental disclosures should not be considered an admission of materiality or legal necessity.

What Was Disclosed

Theravance Biopharma filed an 8-K disclosing three merger-related shareholder lawsuits, thirteen demand letters, and voluntary supplemental proxy disclosures amending the background of the merger section, ahead of a September 18, 2026 shareholder vote on the Zymeworks merger.